一种β-甘氨酸增强的多 (l-乳酸) 生物皮动物电贴片,用于自动供电的心肌梗塞治疗
Wei Sun1, Tongtong Yin2, Ran Wei1
1State and Local Joint Engineering Laboratory for Novel Functional Polymeric Materials, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, P. R. China.
ACS applied materials & interfaces
|February 26, 2026
概括
这项研究引入了一种自动供电,生物可降解的心脏贴片,该贴片由聚氨酸乳酸和β-甘氨酸晶体制成. 该贴片可以增强心脏功能,并促进心肌梗塞 (MI) 后的愈合.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 心血管研究研究心血管研究
背景情况:
- 心脏贴片为心肌梗塞 (MI) 提供机械支持,但往往缺乏用于心肌细胞支持的电机一体化.
- 有效的心脏病发作治疗需要解决电气整合的挑战,目前的心脏贴片材料无法满足这些挑战.
研究的目的:
- 开发一种自动供电,可生物降解的压电心脏贴片,用于改善心肌梗塞 (MI) 治疗.
- 在体外和体内评估新型心脏贴片的生物相容性,电机性能和治疗疗效.
主要方法:
- 使用聚氨酸 (PLLA) 和β-甘氨酸晶体通过高速电回旋制造压电心脏贴片.
- 贴片的压电特性 (系数和灵敏度) 的表征.
- 在体外评估生物相容性和人类静脉内皮细胞 (HUVEC) 对压电刺激的反应.
- 在小鼠MI模型中进行体内植入,以评估心脏功能,纤维化,血管新生和连xin-43 的表达.
主要成果:
- 优化的PLLA-Gly-H补丁显示出高压电性能 (d33 = 32.4 ± 1.6 pC·N−1,灵敏度 = 21.24 ± 0.81 mV·kPa−1).
- 在体外研究显示出优异的生物相容性 (>99%的细胞存活率) 和在刺激下增强的HUVEC传播 (~88.5%覆盖率).
- 在体内植入显著改善心脏功能 (排泄分数:47.7%对35.0%),减少纤维化 (41.5%的减少),促进血管生成 (4.387±0.167血管·mm-2),并增加连xin-43表达 (1.389±0.183%) 在MI模型与MI组相比.
结论:
- 开发的自动供电压电心脏贴片显示了治疗心肌梗塞 (MI) 的巨大潜力.
- 这种可生物降解的贴片通过增强电气整合和心脏修复,为贴片介导的肌痛性心脏病治疗提供了一个有前途的新途径.
相关概念视频
01:19Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...